担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Early detection of mild cognitive impairment (MCI) and dementia is very important to begin appropriate treatment promptly and to prevent disease exacerbation. We investigated the screening accuracy of the Japanese version of Addenbrooke's Cognitive Examination III (ACE-III) to diagnose MCI and dementia. METHODS: The original ACE-III was translated and adapted to Japanese. It was then administered to a Japanese population. The Hasegawa Dementia Scale-revised (HDS-R) and Mini-mental State Examination (MMSE) were also applied to evaluate cognitive dysfunction. In total, 389 subjects (dementia = 178, MCI = 137, controls = 73) took part in our study. RESULTS: The optimal ACE-III cut-off scores to detect MCI and dementia were 88/89 (sensitivity 0.77, specificity 0.92) and 75/76 (sensitivity 0.82, specificity 0.90), respectively. ACE-III was superior to HDS-R and MMSE in the detection of MCI or dementia. The internal consistency, test-retest reliability, and inter-rater reliability of ACE-III were excellent. CONCLUSIONS: ACE-III is a useful cognitive test to detect MCI and dementia. ACE-III may be widely useful in clinical practice.

DOI： 10.1186/s12877-019-1120-4

PubMed

researchmap

担当区分：筆頭著者,　責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

Social cognition has recently been recognized as one of the essential cognitive domains. Some reports suggested that patients with Alzheimer's disease dementia (ADD) presented significant theory of mind deficits even in the mild condition. However, most previous studies included only small numbers of patients with ADD. The present study administered the first-order false belief (Sally-Anne) test to 116 consecutive patients with ADD from the outpatient units of the Memory Clinic and compared the characteristics of the two groups with correct and incorrect answers on the test. Then various clinical characteristics were evaluated. Only 37.1% of patients with ADD correctly answered the Sally-Anne test with the right explanation. Comparison between the two groups of correct and incorrect answers revealed a significant association between the frontal assessment battery score and the result of the Sally-Anne test in the multiple logistic regression analyses. Thus, patients with ADD presented a significant deficit in social cognition even in the mild condition. Frontal dysfunction was thought to be related to the deficits in mild ADD.

DOI： 10.3233/JAD-170621

PubMed

researchmap

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: It is widely supposed that there is no benefit, including extended survival and decreased rate of pneumonia, in patients with severe dementia receiving enteral tube feeding (TF). However, there have been few studies comparing the frequency of pneumonia before and after TF in severe dementia. METHODS: Nine psychiatric hospitals in Okayama Prefecture participated in this retrospective survey. All inpatients fulfilling the entry criteria were evaluated. All subjects suffered from difficulty in oral intake. Attending physicians thought that the patients could not live without long-term artificial nutrition, and they decided whether or not to make use of long-term artificial nutrition from January 1, 2014 to December 31, 2014. RESULTS: We evaluated 58 patients including 46 with TF and 12 without. The mean age of all patients was 79.6 ± 9.0 years old. Patients with probable Alzheimer's disease (n = 38) formed the biggest group, and those with vascular dementia the second (n = 14). Median survival times were 23 months among patients with TF and two months among patients without TF. The start of TF decreased the frequency of pneumonia and the use of intravenous antibiotics. CONCLUSIONS: TF decreased pneumonia and antibiotic use, even in patients with severe dementia. The results of this study do not necessarily indicate that we should administer TF to patients with severe dementia. We should consider the quality of life of patients carefully before deciding the use or disuse of TF for patients with severe dementia.

DOI： 10.1186/s12877-017-0662-6

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Abstract

Agyrophilic grains (AGs) are age-related limbic-predominant lesions in which four-repeat tau is selectively accumulated. Because previous methodologically heterogeneous studies have demonstrated inconsistent findings on the relationship between AGs and dementia, whether AGs affect cognitive function remains unclear. To address this question, we first comprehensively evaluated the distribution and quantity of Gallyas-positive AGs and the severity of neuronal loss in the limbic, neocortical, and subcortical regions in 30 cases of pure argyrophilic grain disease (pAGD) in Braak stages I–IV and without other degenerative diseases, and 34 control cases that had only neurofibrillary tangles with Braak stages I–IV and no or minimal Aβ deposits. Then, we examined whether AGs have independent effects on neuronal loss and dementia by employing multivariate ordered logistic regression and binomial logistic regression. Of 30 pAGD cases, three were classified in diffuse form pAGD, which had evident neuronal loss not only in the limbic region but also in the neocortex and subcortical nuclei. In all 30 pAGD cases, neuronal loss developed first in the amygdala, followed by temporo-frontal cortex, hippocampal CA1, substantia nigra, and finally, the striatum and globus pallidus with the progression of Saito AG stage. In multivariate analyses of 30 pAGD and 34 control cases, the Saito AG stage affected neuronal loss in the amygdala, hippocampal CA1, temporo-frontal cortex, striatum, globus pallidus, and substantia nigra independent of the age, Braak stage, and limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) stage. In multivariate analyses of 23 pAGD and 28 control cases that lacked two or more lacunae and/or one or more large infarctions, 100 or more AGs per × 400 visual field in the amygdala (OR 10.02, 95% CI 1.12–89.43) and hippocampal CA1 (OR 12.22, 95% CI 1.70–87.81), and the presence of AGs in the inferior temporal cortex (OR 8.18, 95% CI 1.03–65.13) affected dementia independent of age, moderate Braak stages (III–IV), and LATE-NC. Given these findings, the high density of limbic AGs and the increase of AGs in the inferior temporal gyrus may contribute to the occurrence of dementia through neuronal loss, at least in cases in a low to moderate Braak stage.

DOI： 10.1186/s40478-024-01828-6

researchmap

その他リンク： https://link.springer.com/article/10.1186/s40478-024-01828-6/fulltext.html

担当区分：筆頭著者,　責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: It has been reported that patients with geriatric psychiatric disorders include many cases of the prodromal stages of neurodegenerative diseases. Abnormal 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane dopamine transporter single-photon emission computed tomography (DAT-SPECT) reveals a nigrostriatal dopaminergic deficit and is considered useful to detect dementia with Lewy bodies and Parkinson's disease as well as progressive supranuclear palsy and corticobasal degeneration. We aimed to determine the proportion of cases that are abnormal on DAT-SPECT in patients with geriatric psychiatric disorders and to identify their clinical profile. METHODS: The design is a cross-sectional study. Clinical findings of 61 inpatients aged 60 years or older who underwent DAT-SPECT and had been diagnosed with psychiatric disorders, but not neurodegenerative disease or dementia were analysed. RESULTS: 36 of 61 (59%) had abnormal results on DAT-SPECT. 54 of 61 patients who had DAT-SPECT (89%) had undergone 123I-metaiodobenzylguanidine myocardial scintigraphy (123I-MIBG scintigraphy); 12 of the 54 patients (22.2%) had abnormal findings on 123I-MIBG scintigraphy. There were no cases that were normal on DAT-SPECT and abnormal on 123I-MIBG scintigraphy. DAT-SPECT abnormalities were more frequent in patients with late-onset (55 years and older) psychiatric disorders (69.0%) and depressive disorder (75.7%), especially late-onset depressive disorder (79.3%). CONCLUSION: Patients with geriatric psychiatric disorders include many cases showing abnormalities on DAT-SPECT. It is suggested that these cases are at high risk of developing neurodegenerative diseases characterised by a dopaminergic deficit. It is possible that patients with geriatric psychiatric disorders with abnormal findings on DAT-SPECT tend to show abnormalities on DAT-SPECT first rather than on 123I-MIBG scintigraphy.

DOI： 10.1136/bmjment-2024-301042

PubMed

researchmap

記述言語：英語  

DOI： 10.1097/YCT.0000000000000973

PubMed

researchmap

記述言語：英語  

DOI： 10.1186/s40478-023-01643-5

PubMed

researchmap

担当区分：責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Autoimmune hypothalamitis is a very rare neuroendocrine disorder that causes central diabetes insipidus, headache, visual impairment, and sometimes cognitive impairment. Autoimmune hypothalamitis may occur in association with autoimmune hypophysitis, including lymphocytic hypophysitis, or in isolation. It is not known whether autoimmune hypothalamitis and autoimmune hypophysitis are consecutive diseases. CASE PRESENTATION: A 52-year-old woman developed autoimmune hypothalamitis 7 years after developing central diabetes insipidus due to lymphocytic hypophysitis, resulting in severe memory impairment. High-dose intravenous methylprednisolone therapy improved her cognitive function and decreased the size of the lesion. CONCLUSION: This case presented a unique clinical course, with a long period of time between the onset of autoimmune hypopituitaritis and the development of autoimmune hypothalamitis.

DOI： 10.1186/s12883-022-02891-z

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.17879/freeneuropathology-2022-4285

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP) and corticobasal degeneration are four-repeat (4R) tauopathies that develop in the presenium or later. Whether these diseases are associated with the occurrence of late-onset psychiatric disorders remains unclear. To facilitate the accumulation of clinicopathological findings regarding this issue, we here present a selected series of 11 cases that clinically developed psychotic disorder (n = 7; age at onset: 41-75 years), depressive disorder (n = 1; 49 years), bipolar disorder (n = 2; 32 and 37 years) and somatoform disorder (n = 1; 88 years), and had at least one pathological hallmark of these tauopathies. The mean age at death was 74.3 years. No case showed dementia, at least in the early stage of the course. Nine cases had AGD. Granular fuzzy astrocytes in the amygdala were noted in all AGD cases and one non-AGD case. Two AGD cases had tufted astrocytes (TAs) in the amygdala but not in the frontal cortex and striatum. Three AGD and two non-AGD cases had TAs in the frontal cortex and/or striatum but not in the amygdala. One AGD case had a small number of astrocytic plaques in the frontal cortex, striatum and globus pallidus. Only one case was diagnosed as atypical PSP according to the NINDS-PSP neuropathological criteria. No case had high-level Alzheimer's disease pathology, Lewy body disease or limbic-predominant age-related TDP-43 encephalopathy. Two cases had mild neuronal loss in the hippocampus and substantia nigra, respectively. Clinicopathological studies focusing especially on early changes of 4R tauopathies, as well as the development of surrogate markers of these diseases, may be necessary for better understanding of the pathogenic backgrounds of late-onset psychiatric disorders.

DOI： 10.1111/neup.12820

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

AIM: Social cognition encompasses facial expression recognition (FER), theory of mind, and empathy. Although studies examining FER in large numbers of patients with mild cognitive impairment (MCI) or dementia are rare, relative preservation of happiness recognition in dementia was reported in some studies. In this study, we examined performance on FER tests and its relationship to clinical demographics and other cognitive function test scores in patients with cognitive decline. METHODS: The present study administered an FER test and several cognitive tests to outpatients at a memory clinic. The FER test presents four facial expressions (happiness, surprise, anger, and sadness). A total of 187 patients were placed in one of the three groups based on their cognitive status: dementia group (n = 63), MCI group (n = 92), and normal cognition group (n = 32). RESULTS: The total scores on the FER test significantly differed among the three groups (normal > MCI > dementia). In the recognition of happiness and surprise, the dementia group had significantly lower scores than the normal cognition group. There were no significant differences in the recognition of anger and sadness scores among the three groups. The FER scores for happiness and surprise were primarily related to executive function scores, but the FER scores for anger and sadness were primarily related to age. CONCLUSIONS: We note the difference in recognition of causative factors among the four emotions (happiness, surprise, anger, sadness). Our study raises serious doubts about the preservation of happiness recognition hypothesis in dementia based on FER tests.

DOI： 10.1111/psyg.12622

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Granular/fuzzy astrocytes (GFAs), a subtype of "aging-related tau astrogliopathy," are noted in cases bearing various neurodegenerative diseases. However, the pathogenic significance of GFAs remains unclear. We immunohistochemically examined the frontal cortex, caudate nucleus, putamen and amygdala in 105 cases composed of argyrophilic grain disease cases (AGD, N = 26), and progressive supranuclear palsy (PSP, N = 10), Alzheimer's disease (AD, N = 20) and primary age-related tauopathy cases (PART, N = 18) lacking AGD, as well as 31 cases bearing other various neurodegenerative diseases to clarify (i) the distribution patterns of GFAs in AGD, and PSP, AD and PART lacking AGD, (ii) the impacts of major pathological factors and age on GFA formation and (iii) immunohistochemical features useful to understand the formation process of GFAs. In AGD cases, GFAs consistently occurred in the amygdala (100%), followed by the putamen (69.2%) and caudate nucleus and frontal cortex (57.7%, respectively). In PSP cases without AGD, GFAs were almost consistently noted in all regions examined (90-100%). In AD cases without AGD, GFAs were less frequent, developing preferably in the putamen (35.0%) and caudate nucleus (30.0%). PART cases without AGD had GFAs most frequently in the amygdala (35.3%), being more similar to AGD than to AD cases. Ordered logistic regression analyses using all cases demonstrated that the strongest independent factor of GFA formation in the frontal cortex and striatum was the diagnosis of PSP, while that in the amygdala was AGD. The age was not significantly associated with GFA formation in any region. In GFAs in AGD cases, phosphorylation and conformational change of tau, Gallyas-positive glial threads indistinguishable from those in tufted astrocytes, and the activation of autophagy occurred sequentially. Given these findings, AGD, PSP, AD and PART cases may show distinct distributions of GFAs, which may provide clues to predict the underlying processes of primary tauopathies.

DOI： 10.1111/bpa.12843

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

BACKGROUND: Early detection of mild cognitive impairment (MCI) and dementia is important to promptly start appropriate intervention. However, it is difficult to examine a patient using long and thorough cognitive tests in a general clinical setting. In this study, we aimed to investigate the diagnostic validity of the Addenbrooke's Cognitive Examination - III (ACE-III), Mini-ACE (M-ACE), Montreal Cognitive Assessment (MoCA), Hasegawa Dementia Scale-Revised (HDS-R), and Mini-Mental State Examination (MMSE) to identify MCI and dementia. METHODS: A total of 249 subjects (controls = 50, MCI = 94, dementia = 105) at a memory clinic participated in this study, and took the ACE-III, M-ACE, MoCA, HDS-R, and MMSE. After all examinations had been carried out, a conference was held, and the clinical diagnoses were established. RESULTS: The areas under the curve (AUC) of the ACE-III, M-ACE, MoCA, HDS-R, and MMSE for diagnosing MCI were 0.891, 0.856, 0.831, 0.808, and 0.782. The AUC of the ACE-III was significantly larger than those of the MoCA, HDS-R, and MMSE. The AUCs of the ACE-III, M-ACE, MoCA, HDS-R, and MMSE for diagnosing dementia were 0.930, 0.917, 0.854, 0.871, and 0.856. Thus, the AUCs of the ACE-III and M-ACE were significantly larger than those of the MoCA, HDS-R, and MMSE. CONCLUSION: The ACE-III is a useful cognitive instrument to detect MCI. For distinguishing dementia patients from non-dementia patients, the ACE-III and M-ACE are superior to the MoCA, HDS-R, and MMSE.

DOI： 10.1111/psyg.12480

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

BACKGROUND: Numerous studies focusing on the burden of caregivers of dementia patients have been published. However, there have been few studies focusing on positive affect as an important factor affecting the caregiver burden, and only a few studies comparing the caregiver burden between different dementia diseases have been reported. METHODS: Three hundred and thirty-seven consecutive caregivers of people with dementia participated in this study. The caregiver burden was evaluated by the short version of the Japanese version of the Zarit Burden Interview. RESULTS: Positive affect scores had a significant relationship with the scores of the short version of the Zarit Burden Interview. Caregivers for patients with dementia with Lewy bodies or frontotemporal dementia suffered from a greater burden than those for patients with Alzheimer's disease dementia. CONCLUSIONS: The caregiver burden differed between people caring for patients with different dementia diseases. Positive affect of dementia patients has a significant relationship with caregiver burden, independently from neuropsychiatric symptoms of patients.

DOI： 10.1111/psyg.12487

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: In medical practice, a patient's loss of competency is a major obstacle when choosing a treatment and a starting treatment program smoothly. A large number of studies have revealed the lack of medical competency in patients with dementia. However, there have been only a few reports focusing on the capacity of patients with mild cognitive impairment (MCI) to make a medical choice. METHODS: In this study, we evaluated the competency of 40 patients with amnestic MCI (aMCI) and 33 normal subjects to make a medical choice using the MacArthur Competence Assessment Tool-Treatment (MacCAT-T). We compared the judgement of a team conference using the recorded semi-structured interview with the clinical judgement of a chief clinician. RESULTS: A team conference concluded that 12 aMCI patients had no competency, and the clinical judgement, without any special interview, judged that five aMCI patients had no competency. All subjects in the control groups were judged to be competent to consent to treatment by both clinicians and the team conference. CONCLUSIONS: Without supplementary tools such as explanatory documents, not a few patients with aMCI were judged by a team conference to have no competency to consent to therapy even in a relatively simple and easy case. In contrast, clinical physicians tended to evaluate the competency of aMCI patients in a generous manner.

DOI： 10.1017/S1041610219000516

PubMed

researchmap

記述言語：英語  

DOI： 10.1186/s40478-019-0672-z

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Neurodegenerative diseases in which tau accumulation plays a cardinal role in the pathogenic process are called tauopathies, and when tau isoforms having four repeats of the microtubule binding sites, four-repeat tau, are selectively accumulated as pathological hallmarks, the term four-repeat tauopathy is used. The major four-repeat tauopathies are progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD). Historically, neuronal cytopathologies, e.g., neurofibrillary tangles and ballooned neurons, were emphasized as characteristic lesions in PSP and CBD. Now, however, astrocytic tau pathologies, i.e., tufted astrocytes (TAs) and astrocytic plaques (APs), are considered to be highly disease-specific lesions. Although granular/fuzzy astrocytes (GFAs) frequently develop in the limbic system in AGD cases, the specificity is not conclusive yet. Some AGD cases have a few TAs, and to a lesser frequency, a few APs in the frontal cortex and subcortical nuclei. The number of astrocytic tau pathologies including TAs and GFAs increases with the progression of AGD. In this paper, histopathological features of astrocytic tau pathologies in PSP, CBD, and AGD are first reviewed. Then, recent findings regarding the coexistence of these tauopathies are summarized from a viewpoint of astrocytic tau pathologies. Further biochemical and pathological studies focusing tau-positive astrocytic lesions may be useful to increase understanding of the pathological process in four-repeat tauopathies and to develop novel therapeutic strategies for patients with these diseases.

DOI： 10.18926/AMO/56066

PubMed

researchmap

記述言語：英語  

The clinical features in cases that have mutations in the microtubule-associated protein tau gene but lack prominent behavioral changes remain unclear. Here, we describe detailed clinical and pathological features of a case carrying the P301L tau mutation that showed only apathy until the middle stage of the course. The mother of this case was suspected to have mild cognitive decline at age 46. However, before she was fully examined, she had a subarachnoid hemorrhage at age 49 and died at age 53. An autopsy was not done. The proband of this pedigree, a 60-year-old right-handed Japanese man at the time of death, began to make mistakes at work at the age of 51 years. Until age 54, he showed only mild apathy with bradykinesia. Insight was well spared. Parkinsonism and echolalia developed at age 55, and pyramidal signs and oral tendency at age 57. Personality change, disinhibition, stereotypy, or semantic memory impairment was not found throughout the course. The final neurological diagnosis was unspecified dementia. Pathological examination demonstrated numerous round four-repeat tau-positive three-repeat tau-negative or perinuclear ring-like neuronal cytoplasmic inclusions with many ballooned neurons in the frontal and temporal cortices and hippocampus. Genetic analysis using frozen brain tissue demonstrated a P301L tau mutation. Among 31 previously reported cases bearing the P301L tau mutation for which the data regarding initial symptoms are available, one clinical case showed only apathy with depression in the early stage. Given these findings, clinicians should be aware that a clinical course characterized only by apathy for several years, which can be misdiagnosed as a psychiatric disorder, is one of the clinical presentations associated with P301L tau mutation.

DOI： 10.1111/neup.12441

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenerative disease. Common first symptoms are dementia, cerebellar ataxia, visual disturbance, and psychiatric symptoms. Seizure as the first symptom of CJD is a very rare finding. CASE PRESENTATION: We experienced an elderly woman who presented initially with status epilepticus following repeated partial seizures in the course of Alzheimer disease (AD) dementia. Anti-convulsive therapy had no effect. Autopsy revealed definite CJD with AD pathology. COCLUSIONS: This is the first reported CJD case presenting with status epilepticus in the course of AD dementia.

DOI： 10.1186/s12883-018-1055-y

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Argyrophilic grain disease (AGD) is a common four-repeat tauopathy in elderly people. While dementia is a major clinical picture of AGD, recent studies support the possibility that AGD may be a pathological base in some patients with mild cognitive impairment, late-onset psychosis, bipolar disorder and depression. AGD often coexists with various other degenerative changes. The frequency of AGD in progressive supranuclear palsy (PSP) cases was reported to range from 18.8% to 80%. The frequency of AGD in corticobasal degeneration (CBD) cases tends to be higher than that in PSP cases, ranging from 41.2% to 100%. Conversely, in our previous study of the frequencies of mild PSP and CBD pathologies in AGD cases, five of 20 AGD cases (25%) had a few Gallyas-positive tufted astrocytes, six cases (30%) had a few granular/fuzzy astrocytes, and one case (5.0%) had a few Gallyas-positive astrocytic plaques in the putamen, caudate nucleus and/or superior frontal gyrus. Both Gallyas-positive tufted astrocytes and Gallyas-negative tau-positive granular/fuzzy astrocytes preferentially developed in the putamen, caudate nucleus and superior frontal cortex in AGD cases, being consistent with the predilection sites of Gallyas-positive tufted astrocytes in PSP cases. Further, in AGD cases, the quantities of Gallyas-positive tufted astrocytes, overall tau-positive astrocytes, and tau-positive neurons in the subcortical nuclei and superior frontal cortex were significantly correlated with Saito AGD stage, respectively. The frequency of AGD in AD cases was reported to reach up to 25% when using four-repeat tau immunohistochemistry. Pretangles are essential pathologies in AGD; however, the Braak stage of three-repeat tau-positive NFTs, which may indicate mild AD pathology or primary age-related tauopathy, was not correlated with Saito AGD stage. Clinicians should be aware of the possibility that coexisting AGD may impact clinical and radiological features in cases of other degenerative diseases.

DOI： 10.1111/neup.12429

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1159/000486093

Web of Science

PubMed

researchmap

記述言語：英語  

It is very rare that cases of Pick's disease, a representative three-repeat (3R) tauopathy, also have significant four-repeat (4R) tau accumulation. Here, we report a Pick's disease case that clinically showed behavioral variant frontotemporal dementia without motor disturbance during the course, and pathologically had 3R tau-positive Pick bodies as well as numerous 4R tau-positive neuronal cytoplasmic inclusions (NCIs). Abundant 3R tau-positive 4R tau-negative spherical or horseshoe-shaped Pick bodies were found in the frontotemporal cortex, limbic region, striatum and pontine nucleus. On the other hand, many 4R tau-positive, 3R tau-negative, Gallyas-negative dot-, rod- or intertwined skein-like NCIs were found mainly in the subthalamic nucleus, pontine nucleus, inferior olivary nucleus and cerebellar dentate nucleus. Tufted astrocytes, astrocytic plaques, argyrophilic grains or globular glial inclusions were absent. Double-labeling immunofluorescence demonstrated that 3R tau was hardly accumulated in 4R tau-positive inclusions. On tau immunoblotting, while 60 and 64 kDa bands were demonstrated in the frontal cortex, 60, 64 and 68 kDa bands, as well as the 33 kDa tau fragments that are reported to be characteristic of progressive supranuclear palsy brains, were found in the basal ganglia and cerebellum. No mutation was identified in the tau gene. The present case suggests that, although probably rare, some Pick's disease cases have non-negligible 4R tau pathology in the subcortical nuclei, and that such 4R tau pathology can affect the evaluation of the distribution of AT8-positive tau pathology in Pick's disease cases.

DOI： 10.1111/neup.12394

PubMed

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本発達障害学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

CiNii Books

researchmap

担当区分：筆頭著者,　責任著者   記述言語：日本語   出版者・発行元：日本発達障害学会  

CiNii Books

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本発達障害学会  

researchmap

記述言語：日本語   出版者・発行元：(福)旭川荘  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(福)旭川荘  

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）  

Web of Science

researchmap

記述言語：日本語   出版者・発行元：医学書院  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)北隆館  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(福)旭川荘  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本発達障害学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本発達障害学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2019316199

記述言語：日本語   出版者・発行元：星和書店  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2019314987

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：社会福祉法人 認知症介護研究・研修東京センター  

DOI： 10.24745/jdcr.3.0_38

CiNii Article

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2019052665

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018299500

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018175955

記述言語：日本語   出版者・発行元：(一社)日本てんかん学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本精神神経学会  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018249732

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本発達障害学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018063643

記述言語：日本語   出版者・発行元：ワールドプランニング  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018033048

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)ワールドプランニング  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本総合病院精神医学会  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本精神神経学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(一社)日本認知症学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：日本臨床精神神経薬理学会・日本神経精神薬理学会  

researchmap

記述言語：日本語   出版者・発行元：愛媛県公営企業管理局県立病院課  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：愛媛県公営企業管理局県立病院課  

J-GLOBAL

researchmap

開催年月日： 2024年10月25日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2024年7月9日 - 2024年7月12日

記述言語：英語   会議種別：ポスター発表  

researchmap

開催年月日： 2023年10月13日 - 2023年10月14日

会議種別：ポスター発表  

researchmap

開催年月日： 2023年10月13日 - 2023年10月14日

会議種別：シンポジウム・ワークショップ パネル（指名）  

researchmap

開催年月日： 2022年9月16日 - 2022年9月18日

researchmap

開催年月日： 2022年9月9日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2022年6月24日 - 2022年6月26日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2022年2月15日 - 2022年3月15日

記述言語：日本語   会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

researchmap

開催年月日： 2021年11月26日 - 2021年11月28日

会議種別：ポスター発表  

researchmap

開催年月日： 2021年11月11日 - 2021年11月12日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2021年11月11日 - 2021年11月12日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2021年11月11日 - 2021年11月12日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2021年9月16日 - 2021年9月18日

会議種別：口頭発表（一般）  

researchmap

開催年月日： 2021年9月16日 - 2021年9月18日

researchmap

開催年月日： 2021年6月6日 - 2021年6月8日

会議種別：口頭発表（一般）  

researchmap

会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

researchmap

会議種別：シンポジウム・ワークショップ パネル（指名）  

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：口頭発表（一般）  

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

会議種別：ポスター発表  

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：シンポジウム・ワークショップ パネル（指名）  

researchmap

会議種別：ポスター発表  

researchmap

researchmap

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：口頭発表（一般）  

researchmap

researchmap

会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

researchmap

会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

researchmap

会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：口頭発表（一般）  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

researchmap

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap

会議種別：ポスター発表  

researchmap